| # | Title | Journal | Year | Citations |
|---|
|
| 1 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1,840 |
| 2 | Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial | Lancet, The | 2017 | 775 |
| 3 | Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer | JAMA Oncology | 2018 | 775 |
| 4 | Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab | Science Translational Medicine | 2011 | 557 |
| 5 | Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2022 | 494 |
| 6 | Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer | JAMA Oncology | 2020 | 482 |
| 7 | Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2019 | 432 |
| 8 | Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial | Lancet Oncology, The | 2017 | 416 |
| 9 | Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial | Lancet Oncology, The | 2015 | 365 |
| 10 | Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib | Journal of Clinical Oncology | 2006 | 354 |
| 11 | Gefitinib — a novel targeted approach to treating cancer | Nature Reviews Cancer | 2004 | 350 |
| 12 | Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904) | Journal of Clinical Oncology | 2006 | 346 |
| 13 | Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies | International Journal of Cancer | 2020 | 327 |
| 14 | Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study | Lancet Oncology, The | 2019 | 274 |
| 15 | Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment | Annals of Oncology | 2017 | 250 |
| 16 | Skeletal metastases in non-small cell lung cancer: A retrospective study | Lung Cancer | 2007 | 240 |
| 17 | Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors | Cancer Discovery | 2020 | 240 |
| 18 | Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) | Annals of Oncology | 2019 | 238 |
| 19 | Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies | Nature Medicine | 2020 | 238 |
| 20 | Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival | Journal of the National Cancer Institute | 2017 | 201 |
| 21 | Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) | British Journal of Cancer | 2008 | 200 |
| 22 | Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) | Annals of Oncology | 2016 | 200 |
| 23 | Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT) | Clinical Cancer Research | 2019 | 198 |
| 24 | The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC | Journal of Thoracic Oncology | 2017 | 196 |
| 25 | Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab | Journal of Thoracic Oncology | 2018 | 194 |
| 26 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS | Annals of Oncology | 2019 | 179 |
| 27 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS | Annals of Oncology | 2019 | 174 |
| 28 | FOXQ1 Is Overexpressed in Colorectal Cancer and Enhances Tumorigenicity and Tumor Growth | Cancer Research | 2010 | 172 |
| 29 | Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆ | Annals of Oncology | 2021 | 171 |
| 30 | Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study | Lancet Oncology, The | 2019 | 167 |
| 31 | Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer | Lung Cancer | 2015 | 166 |
| 32 | Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer | Cancer Discovery | 2022 | 164 |
| 33 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Gastric Cancer | 2020 | 162 |
| 34 | Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer | British Journal of Cancer | 2011 | 156 |
| 35 | Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer | Clinical Cancer Research | 2020 | 155 |
| 36 | Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients | British Journal of Cancer | 2008 | 152 |
| 37 | Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer | Clinical Cancer Research | 2012 | 150 |
| 38 | Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial | The Lancet Gastroenterology and Hepatology | 2017 | 150 |
| 39 | Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer | British Journal of Cancer | 2003 | 145 |
| 40 | Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer | Investigational New Drugs | 2017 | 136 |
| 41 | Role of ERK-BIM and STAT3-Survivin Signaling Pathways in ALK Inhibitor–Induced Apoptosis in EML4-ALK–Positive Lung Cancer | Clinical Cancer Research | 2011 | 132 |
| 42 | Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial | Lancet Oncology, The | 2016 | 127 |
| 43 | DS‐8201a, a new HER2‐targeting antibody–drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2‐positive gastric cancer T‐DM1 resistance | International Journal of Cancer | 2017 | 126 |
| 44 | First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer? | International Journal of Molecular Sciences | 2019 | 125 |
| 45 | MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations | Journal of Thoracic Oncology | 2011 | 123 |
| 46 | The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer | Oncogene | 2015 | 118 |
| 47 | A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903) | Cancer | 2012 | 116 |
| 48 | B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity | Clinical Cancer Research | 2018 | 116 |
| 49 | Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1) | British Journal of Cancer | 2014 | 115 |
| 50 | Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor | JAMA Oncology | 2021 | 115 |
